Manufacture of adoptive cell therapies at academic cancer centers: scientific, safety and regulatory challenges


Por: Saini KS, Svane IM, Juan-Otero M, Barlesi F and André F

Publicada: 1 ene 2022 Ahead of Print: 1 dic 2021
Resumen:


Filiaciones:
Saini KS:
 Labcorp Drug Development Inc., Princeton, NJ, USA

Svane IM:
 National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark

Juan-Otero M:
 Department of Immunology, Hospital Clinic, IDIBAPS, Immunotherapy platform Hospital Sant Joan de Déu, Universidad de Barcelona, Barcelona, Spain

Barlesi F:
 Department of Medical Oncology, Institut Gustave Roussy, Villejuif

 Aix Marseille University, CNRS, INSERM, CRCM, Marseille, France

André F:
 Institut Gustave Roussy, INSERM UMR981, Université Paris Saclay, Paris, France
ISSN: 09237534





ANNALS OF ONCOLOGY
Editorial
ELSEVIER, RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS, Países Bajos
Tipo de documento: Editorial Material
Volumen: 33 Número: 1
Páginas: 6-12
WOS Id: 000731865200002
ID de PubMed: 34655734

MÉTRICAS